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L
eber congenital amaurosis 
(LCA) is a generic term used 
to describe a heterogeneous 
group of inherited disorders that 
result in severe loss of rod and cone 
photoreceptor function in infancy 
and early childhood. Although each 
individual disorder is rare, LCA 
accounts for 3%–5% of childhood 
blindness [1]. 
To date, ten different genes have 
been implicated in such early onset 
retinal dystrophies. The genes are 
expressed in the photoreceptors 
or the underlying retinal pigment 
epithelium (RPE), and encode a 
variety of proteins, including structural 
proteins, transcription factors, and key 
components of the phototransduction 
cascade and the visual cycle.
The Visual Cycle
Light perception in vertebrates is 
mediated by a group of G protein–
coupled receptors called opsins, which 
are bound to a chromophore (light-
absorbing compound), 11-cis-retinal, 
derived from vitamin A. Absorption 
of light induces an 11-cis to all-trans 
isomerisation of the chromophore, 
and the ensuing conformational 
change initiates the visual transduction 
cascade. In order for the activated 
opsin to participate again in the visual 
process, the all-trans-retinal must be 
isomerised back to the 11-cis form via 
an enzymatic pathway, the visual cycle 
(Figure 1). This occurs mainly within 
the RPE. 
Genes encoding a number of 
enzymes within the visual pathway 
have been implicated in LCA, namely, 
RPE65 (retinoid isomerase), retinal 
dehydrogenase 12, and lecithin:retinol 
acyl transferase (LRAT). The genetic 
mutations lead to a lack of 11-cis-
retinal, resulting in severe loss of 
photoreceptor function and ultimately 
in cell death. Therapeutic approaches 
aimed at restoring levels of 11-cis-retinal 
by either improving enzyme function or 
using other biochemical strategies hold 
promise for restoring visual function. 
The development of good animal 
models of LCA is an essential ﬁ  rst step 
in developing effective therapies.
Promising Treatments in a Mouse 
Model
Batten et al., in this issue of PLoS 
Medicine, report very encouraging 
results of two different therapeutic 
approaches in the Lrat knockout 
(Lrat-/-) mouse [2]. The mutant 
mice show an early onset rod–cone 
dystrophy and, as in the human 
disorder, have disease conﬁ  ned to 
the eye. The mouse model appears to 
faithfully reproduce the phenotype 
seen in humans with Lrat deﬁ  ciency. 
In the ﬁ  rst approach, the authors used 
gene therapy with subretinal injection 
of a recombinant adeno-associated 
virus carrying the Lrat gene. Treated 
animals showed high expression of Lrat 
in the RPE adjacent to the injection 
site, markedly increased levels of visual 
pigment, and improvement of rod 
photoreceptor function measured 
electrophysiologically. The rescue of 
retinal function peaked at six weeks 
and then slowly declined. The reasons 
for the lack of sustained rescue are 
unclear. 
A second approach was to use 
the orally administered pro-drugs 
9-cis-retinyl acetate and 9-cis-retinyl 
succinate to bypass the Lrat stage of the 
visual cycle. (9-cis-retinoids were chosen 
as they are easier to synthesise and are 
more stable than 11-cis-forms.) Again, 
rescue of photoreceptor function 
could be unequivocally demonstrated. 
Furthermore, treatment with both 
gene therapy and synthetic retinoids 
was more effective than treatment with 
either alone.
Clinical Implications
What is the relevance of these results 
for patients with early onset retinal 
dystrophies and their clinicians? 
Clearly, there is cause for optimism in 
that treatment may become available 
within the next few years. Gene 
therapy is perhaps the most promising 
approach. Photoreceptor rescue has 
now been demonstrated in a number 
of animal models of inherited retinal 
disease, including mice and dogs 
that lack RPE65 [3]. The ﬁ  rst gene 
therapy trial in humans with early 
onset retinal dystrophies as a result 
of mutations in RPE65 is due to start 
within the next two years, and if this is 
successful, treatment of other disorders 
such as Lrat deﬁ  ciency will follow. 
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Figure 1. The Visual Cycle 
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However, unlike RPE65, there is no 
large animal model of Lrat deﬁ  ciency, 
and patients with Lrat deﬁ  ciency are 
extremely rare; these two problems may 
limit the development of a treatment 
trial in humans. To date, only three 
patients with Lrat deﬁ  ciency have 
been described, and there is very 
limited information about the clinical 
phenotype and natural history. 
What about dietary treatment? This 
has been used with limited success 
in other rare retinal dystrophies 
in humans, for example, Refsum 
disease and gyrate atrophy, where 
the biochemistry of the disorder is 
understood. The results of Batten and 
colleagues’ study suggest that Lrat 
deﬁ  ciency may also respond to dietary 
treatment [2]. It is very interesting that 
9-cis-retinoids can replace 11-cis-retinal, 
and partially restore photoreceptor 
function. However, as the authors 
caution, there is much more work 
that needs to be done before such 
compounds can be used in humans. 
We will need to know whether 9-cis-
retinoids are well tolerated in humans, 
whether there is any retinal or systemic 
toxicity, and whether retinal function 
is improved long term with prevention 
of cell death. Will the treatment be 
effective relatively late in the disease 
process when most patients tend to 
be diagnosed, or is early treatment 
essential? 
The Next Steps
Batten and colleagues’ excellent study 
highlights the improvements that are 
being made in our understanding of the 
disease mechanisms in inherited retinal 
disease [2]. This knowledge will lead to 
the development of novel therapies for 
speciﬁ  c forms of disease. The challenge 
for clinicians is to be prepared for 
treatment trials. We need to identify 
the genetic mutations causing retinal 
degeneration in our patients, carefully 
characterise the phenotype and natural 
history of disease, and identify those 
patients who may beneﬁ  t from the new 
therapeutic approaches.  
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